Recently, the BET family has been systematically explored as the treatment targets, and relevant inhibitors as antitumor agents have demonstrated remarkable clinical inhibitory effect, like JQ1 targeting BRD4 in prostate cancer.45, 46. Here, DNER is linked to prostate carcinoma.